Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital Tuebingen
Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable metastasis. The antibody is directed against epitops of human CD28 and the melanoma associated surface antigen HMV-MAA. Treatment over 5 days with dose escalation.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
malignant melanoma stage III/IV
injectable soft tissue metastasis
informed consent given
Karnofsky \>= 70%
You may not be if
additional chemotherapeutical treatment
systemic glucocorticoids
brain metestasis
other malignancies
Clareo Health | Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
